Celltrion closer to developing Covid-19 treatment, plans to launch self-testing kit

Credit: Shutterstock.com/ Plufflyman

Celltrion Group has successfully completed the first step of developing an antiviral treatment to fight Covid-19. It’s now aiming to launch a rapid self-testing diagnostic kit that, it says, could provide results within 15-20 minutes.

These are the latest milestones in the South Korean biotech’s ongoing efforts to fight the coronavirus pandemic.

The group has been selected as a preferred developer for a monoclonal antibody project to treat and prevent Covid-19 by the Korea Centres for Disease Control (KCDC). Korea was one of the first countries to be affected by the global pandemic.

Celltrion has identified the library of antibodies sourced from the blood of recovered patients in Korea, which are thought to be involved in neutralising the virus and may contribute to recovery from Covid-19.

These antibodies are undergoing further screening processes to identify those that are most effective in neutralising the virus causing Covid-19.

Once identified, it says these will form the basis of the antiviral treatment to be tested through pre-clinical and clinical trials around the world in the third quarter of 2020.

Moreover, Celltrion plans to develop a ‘super antibody’ that can attach and neutralise all kinds of coronavirus related strains, such as those causing Covid-19 and SARS, enabling further protection against unforeseen or unexpected mutations.

The Group said it hopes that the ‘super antibody’ candidate could contribute towards preparedness for potential future pandemic situations.

Alongside therapeutic antibody development, Celltrion aims to launch a rapid self-testing diagnostic kit in the summer of this year.

The kit will focus on the gene that encodes the surface spike (S) protein – an essential glycoprotein for viral entry into human host cells. The kit is designed to show results within 15-20 minutes, with optimised sensitivity, specificity and improved accuracy features.

Once it has gained a CE mark, the rapid self-testing diagnostic kit will become available throughout Europe through Celltrion Healthcare.

Celltrion said it plans to apply for device authorisation from the FDA in the US and other regulatory authorities after acquiring relevant data.

“Our Covid-19 antiviral treatment is designed to train the immune system to make antibodies that recognise and block the spike protein that the virus uses to enter human cells,” said Ki-Sung Kwon, Head of R&D Division at Celltrion.

“Antibodies that bond to the Covid-19 antigen will also be used to develop a diagnostic kit. We implemented an emergency preparedness plan at the very start of the Covid-19 outbreak leveraging our unique antibody discovery, development and manufacturing technologies.”

LEAVE A REPLY

Please enter your comment!
Please enter your name here